Broad-Spectrum Antibiotics End of Life Cancer
- This article discusses a large South Korean study examining antibiotic use in patients with advanced cancer during the last six months of their lives.
- * timing of Antibiotic Use: Antibiotic prescriptions peak 3-1 months before death, while total antibiotic consumption (days of therapy) peaks 1 month to 2 weeks before death.
- * drivers of Timing: The timing likely reflects a decline in physical function leading to more hospitalizations and a tendency to prescribe antibiotics for fever or potential infection,...
Summary of the Article & Key Takeaways:
This article discusses a large South Korean study examining antibiotic use in patients with advanced cancer during the last six months of their lives. Here’s a breakdown of the key findings and insights:
Key Findings:
* timing of Antibiotic Use: Antibiotic prescriptions peak 3-1 months before death, while total antibiotic consumption (days of therapy) peaks 1 month to 2 weeks before death. This isn’t a steady use throughout the final months, but concentrated in specific windows.
* High Prevalence: Over half (55.9%) of advanced cancer patients receive at least one broad-spectrum antibiotic in their last six months.
* Hematologic vs.Solid Tumors: Patients with hematologic malignancies (blood cancers like leukemia) receive significantly more antibiotics than those with solid tumors. This is due to deeper immune suppression.
* Specific Cancer Differences: Leukemia patients had higher odds of receiving antibiotics and higher consumption compared to lung cancer patients in the final week of life.
Expert Insights (Dr. Shin Hye Yoo):
* drivers of Timing: The timing likely reflects a decline in physical function leading to more hospitalizations and a tendency to prescribe antibiotics for fever or potential infection, even without a clear diagnosis.
* Implications for Hematologic malignancies: The severe immune suppression in blood cancers makes home care and hospice more challenging, leading to prolonged and intensive antibiotic use, perhaps hindering goal-concordant care.
* Strategies for Alignment: The clustered timing of antibiotic use presents an opportunity for more intentional decision-making. however, the difficulty in predicting when a patient is entering the final phase of life is a major challenge.
Overall Message:
The study highlights a critical window for antimicrobial stewardship and improved end-of-life care in cancer patients. By understanding when antibiotics are being used, and recognizing the unique needs of patients with hematologic malignancies, healthcare providers can better align antibiotic decisions with patient goals and improve quality of life.
The article ends mid-sentence, but the core message is clear: focused interventions during specific timeframes before death can potentially improve antibiotic stewardship and ensure care aligns with patient preferences.